Maher Issa

1.3k total citations
26 papers, 965 citations indexed

About

Maher Issa is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Maher Issa has authored 26 papers receiving a total of 965 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 7 papers in Hematology and 6 papers in Genetics. Recurrent topics in Maher Issa's work include Rheumatoid Arthritis Research and Therapies (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Dermatology and Skin Diseases (6 papers). Maher Issa is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Dermatology and Skin Diseases (6 papers). Maher Issa collaborates with scholars based in United States, Japan and Germany. Maher Issa's co-authors include Tsutomu Takeuchi, Peter C. Taylor, Terence Rooney, Kevin Winthrop, Gerd R Burmester, Josef S Smolen, Chadi Saifan, Aleksandra Vlajnic, Guillermo E. Umpierrez and Anabela Cardoso and has published in prestigious journals such as Neurology, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Maher Issa

26 papers receiving 943 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maher Issa United States	19	493	182	168	163	151	26	965
Odirlei André Monticielo Brazil	21	585 1.2×	105 0.6×	76 0.5×	89 0.5×	215 1.4×	82	1.1k
Z. Reguiaï France	17	318 0.6×	71 0.4×	89 0.5×	200 1.2×	365 2.4×	60	834
Giacomo Caldarola Italy	23	298 0.6×	95 0.5×	85 0.5×	570 3.5×	281 1.9×	93	1.2k
Angela Nagel Germany	11	194 0.4×	51 0.3×	32 0.2×	43 0.3×	239 1.6×	28	528
Zoltán Szekanecz Hungary	12	279 0.6×	63 0.3×	71 0.4×	57 0.3×	150 1.0×	24	653
Maria Gabriella Raimondo Germany	13	413 0.8×	154 0.8×	81 0.5×	17 0.1×	61 0.4×	33	745
Kristina Albertsson Sweden	12	756 1.5×	237 1.3×	54 0.3×	10 0.1×	129 0.9×	12	984
Anders Gülfe Sweden	13	829 1.7×	283 1.6×	44 0.3×	37 0.2×	103 0.7×	21	1.1k
Thomas Salko United States	5	333 0.7×	212 1.2×	82 0.5×	720 4.4×	244 1.6×	5	1.6k
Aurélie Najm France	16	455 0.9×	163 0.9×	74 0.4×	48 0.3×	52 0.3×	47	869

Countries citing papers authored by Maher Issa

Since Specialization

Citations

This map shows the geographic impact of Maher Issa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maher Issa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maher Issa more than expected).

Fields of papers citing papers by Maher Issa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maher Issa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maher Issa. The network helps show where Maher Issa may publish in the future.

Co-authorship network of co-authors of Maher Issa

This figure shows the co-authorship network connecting the top 25 collaborators of Maher Issa. A scholar is included among the top collaborators of Maher Issa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maher Issa. Maher Issa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morand, Eric F., Josef S Smolen, Michelle Petri, et al.. (2023). Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD Open. 9(3). e003302–e003302. 5 indexed citations

Wollenberg, Andreas, Leon Kircik, Eric L. Simpson, et al.. (2023). Pooled Analysis of Baricitinib Tolerability in Patients with Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events from 8 Clinical Trials. Dermatitis. 34(4). 308–314. 5 indexed citations

Taylor, Peter C., Thomas Bieber, Rieke Alten, et al.. (2023). Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications. Advances in Therapy. 40(4). 1867–1883. 24 indexed citations

Bieber, Thomas, Norito Katoh, Eric L. Simpson, et al.. (2022). Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. Journal of Dermatological Treatment. 34(1). 2161812–2161812. 32 indexed citations

Bieber, Thomas, Eugen Feist, Alan D. Irvine, et al.. (2022). A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Advances in Therapy. 39(11). 4910–4960. 42 indexed citations

Taylor, Peter C., Tsutomu Takeuchi, Gerd R Burmester, et al.. (2021). Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Annals of the Rheumatic Diseases. 81(3). 335–343. 106 indexed citations

King, Brett, Catherine Maari, Edward Lain, et al.. (2021). Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. American Journal of Clinical Dermatology. 22(3). 395–405. 32 indexed citations

Gooderham, Melinda, Jamie Weisman, Orin M. Goldblum, et al.. (2021). 25977 Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib. Journal of the American Academy of Dermatology. 85(3). AB77–AB77. 2 indexed citations

Maari, Catherine, Edward Lain, Jonathan I. Silverberg, et al.. (2021). 27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials. Journal of the American Academy of Dermatology. 85(3). AB127–AB127. 1 indexed citations

10.

Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2020). Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. The Lancet Rheumatology. 2(6). e347–e357. 55 indexed citations

11.

Winthrop, Kevin, Masayoshi Harigai, Mark C. Genovese, et al.. (2020). Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 79(10). 1290–1297. 66 indexed citations

12.

Tanaka, Yoshiya, Bruno Fautrel, Edward Keystone, et al.. (2019). Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 78(7). 890–898. 23 indexed citations

13.

Winthrop, Kevin, et al.. (2019). Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Research & Therapy. 21(1). 102–102. 37 indexed citations

14.

Harigai, Masayoshi, Tsutomu Takeuchi, Josef S Smolen, et al.. (2019). Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. Modern Rheumatology. 30(1). 36–43. 41 indexed citations

15.

Genovese, Mark C., Josef S Smolen, Tsutomu Takeuchi, et al.. (2019). THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 308–309. 21 indexed citations

16.

Taylor, Peter C., Michael E. Weinblatt, Gerd R Burmester, et al.. (2019). Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis & Rheumatology. 71(7). 1042–1055. 134 indexed citations

17.

Tanaka, Yoshiya, Iain B. McInnes, Peter C. Taylor, et al.. (2018). Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis. Arthritis & Rheumatology. 70(12). 1923–1932. 26 indexed citations

18.

Jazieh, Abdul Rahman, et al.. (2012). Use of Complementary and Alternative Medicine by Patients with Cancer in Saudi Arabia. The Journal of Alternative and Complementary Medicine. 18(11). 1045–1049. 88 indexed citations

19.

Umpierrez, Guillermo E., Maher Issa, & Aleksandra Vlajnic. (2006). Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Current Medical Research and Opinion. 22(4). 751–759. 62 indexed citations

20.

Weinshenker, Brian G., Maher Issa, & Jon C. Baskerville. (1996). Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology. 46(6). 1613–1619. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact